Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are ...

Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from ...

Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and ...

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target of $164.00. The company’s shares closed yesterday at $55.06.

Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...

In trading on Tuesday, shares of Viking Therapeutics Inc (Symbol: VKTX) crossed below their 200 day moving average of $61.13, changing hands as low as $58.39 per share. Viking Therapeutics Inc ...